Back to results
US 2003/0073076 A1Published application
Compositions and methods for the treatment and diagnosis of cardiovascular disease
OwnerDean A Falbinventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerDean A Falbinventor
Estimating the term…
The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.
A method for identifying a substance to be tested for an ability to ameliorate symptoms of a fibroproliferative disease or oncogenic related disorder comprising, assaying the ability of the substance to modulate the expression of, or the activity of the encoded protein product of the rchd534 gene or the fchd540 gene.
A method for enhancing TGF-β signalling in a cell, comprising contacting a cell expressing the fchd540 gene with a substance that reduces the expression of, or the activity of the encoded protein product of, the fchd540 gene, such that TGF-β signalling in the cell is enhanced.
A method for ameliorating symptoms of fibroproliferative disease or an oncogenic related disorder comprising administering a substance that reduces the expression of, or the activity of the encoded protein product of, the fchd540 gene, to a patient exhibiting such symptoms.
A method for enhancing TGF-β signalling in a cell, comprising contacting a cell expressing the rchd534 gene with a substance that reduces the expression of, or the activity of the encoded protein product of, the rchd534 gene, such that TGF-β signalling in the cell is enhanced.
A method for ameliorating symptoms of fibroproliferative disease or an oncogenic related disorder comprising administering a substance that reduces the expression of, or the activity of the encoded protein product of, the rchd534 gene, to a patient exhibiting such symptoms.
A method for diagnosing a fibroproliferative disease or an oncogenic related disorder comprising detecting the level of fchd540 transcript or rchd534 transcript present in a patient sample.
A method for diagnosing a fibroproliferative disease or an oncogenic related disorder comprising detecting fchd540 or rchd534 protein level or protein activity present in a patient sample.
A method for characterizing a fibroproliferative disease or oncogenic related disorder comprising, assaying, in a patient sample, overexpression of a gene encoding the fchd531 protein, the fchd540 protein or the rchd534 protein relative to expression in a control sample.
The method of claim 51, wherein the oncogenic related disorder is pancreatic cancer.
A method for monitoring the efficacy of a compound in clinical trials for the treatment of a fibroproliferative disease or oncogenic related disorder comprising, assaying, in a patient sample, overexpression of a gene encoding the fchd540 protein or the rchd534 protein relative to expression in a control sample.
Dependencies are inferred from the claim text.